A Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients with Idiopathic Pulmonary Fibrosis (IPF).
Active, not recruitingCTIS2024-511330-13-00
Puretech Lyt 100 Inc.Idiopathic Pulmonary Fibrosis
Start: 2023-01-17Target: 14Updated: 2025-12-30